Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-ascending dose study of LY3549492 in Japanese participants with type 2 diabetes mellitus and healthy volunteers
jRCT2071240136Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naperiglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment-emergent adverse events and serious adverse events related to study drug. Started May 2025; status: completed.
02
Drugs
naperiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2071240136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240136.